WHO Prioritizes Candidate Vaccines and Therapeutics for Bundibugyo Virus
WHO experts urged clinical trials for three experimental Ebola treatments and said no approved Bundibugyo-specific vaccines or therapies exist.
- On Thursday, the World Health Organization recommended prioritizing three experimental treatments for the Bundibugyo strain of Ebola, which currently lacks licensed therapies for affected patients.
- The outbreak of Bundibugyo virus disease continues in the Democratic Republic of the Congo and Uganda, prompting the agency to convene global experts to identify potential medical countermeasures.
- Experts prioritized Mapp Biopharmaceutical's MBP134 and Regeneron's maftivimab, both monoclonal antibodies, along with combination therapy approaches for clinical trials among confirmed cases.
- The International AIDS Vaccine Initiative single-dose candidate remains the most promising vaccine option, while researchers assess whether Merck's licensed Ervebo vaccine offers protection against the Bundibugyo strain.
- Working with the Africa Centres for Disease Control and Prevention , WHO will implement ethical research protocols, with candidate vaccines requiring seven to nine months before trial readiness.
19 Articles
19 Articles
Experts evaluate promising Ebola treatments, including vax candidate from Oxford/Serum Institute
Advisory groups convened by the World Health Organization have considered promising candidates for prioritisation and evaluation in clinical trials, including a candidate vaccine ChAdOx1 Bundibugyo being developed by Oxford University/Serum Institute of India. The vaccine could potentially become available within two to three months for efficacy assessment through a clinical trial, said the WHO
On Thursday 28 May, WHO published its first recommendations on vaccines and experimental treatments against Ebola Bundibugyo. No vaccine or treatment is currently registered against this rare strain of the virus, but some candidates have been considered promising enough to be evaluated in clinical trials. Highly anticipated recommendations as the epidemic affects DRC and Uganda.
WHO prioritizes candidate vaccines and therapeutics for Bundibugyo virus
In response to the current outbreak of Ebola disease caused by Bundibugyo virus occurring in the Democratic Republic of the Congo, with cases also reported in Uganda, WHO convened several of its expert and advisory groups.
In Congo's conflict zones, Ebola is spreading faster than doctors can track
WHO said experimental vaccines and treatments for the Bundibugyo Ebola outbreak must be tested only through proper clinical trials. The warning comes as infections spread in conflict-hit eastern Congo, where delayed detection and weak healthcare are hampering control.
Coverage Details
Bias Distribution
- 55% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
